Reversible tumorigenesis induced by deficiency of vasodilator-stimulated phosphoprotein

Molecular and Cellular Biology

Volumn 19, Issue 5, 1999, Pages 3696-3703

  Liu, Keyi ^a   Li, Limin ^a   Nisson, Paul E ^b   Gruber, Chris ^b   Jessee, Joel ^b   Cohen, Stanley N ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Life Technologies Inc   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOPROTEIN; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; CELL DIVISION; CELL ISOLATION; COLONY FORMATION; CONTACT INHIBITION; GENE INACTIVATION; GROWTH REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RNA SYNTHESIS;

ANIMALIA; MUS MUSCULUS;

EID: 0032955274     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.19.5.3696     Document Type: Article

References (70)

1. Ahern-Djamali, S. M., A. R. Comer, C. Bachmann, A. S. Kastenmeier, S. K. Reddy, M. C. Beckerle, U. Walter, and F. M. Hoffmann. 1998. Mutations in Drosophila enabled and rescue by human vasodilator-stimulated phosphoprotein (VASP) indicate important functional roles for Ena/VASP homology domain 1 (EVH1) and EVH2 domains. Mol. Biol. Cell 9:2157-2171.
2. Aszodi, A., A. Pfeifer, M. Ahmad, M. Glauner, X. H. Zhou, L. Ny, K. E. Andersson, B. Kehrel, S. Offermanns, and R. Fassler. 1999. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 18:37-48.
3. Beckerle, M. C. 1997. Zyxin: zinc fingers at sites of cell adhesion. Bioessays 19:949-957.
4. Belkin, A. M., and V. E. Koteliansky. 1987. Interaction of iodinated vinculin, metavinculin and α-actinin with cytoskeletal proteins. FEBS Lett. 220:291-294.
5. Bello, M. J., P. E. Leone, P. Nebreda, M. E. Kusak, J. M. Decampos, J. Vaquero, J. L. Sarasa, A. Pestana, and J. A. Rey. 1995. Molecular abnormalities of chromosome 19 in malignant gliomas: preferential involvement of the 19q13.2-19q13.4 region. Int. J. Oncol. 6:655-658.
6. Ben-Ze'ev, A. 1985. The cytoskeleton in cancer cells. Biochim. Biophys. Acta 780:197-212.
7. Bicher, A., K. Ault, A. Kimmelman, D. Gershenson, E. Reed, and B. Liang. 1997. Loss of heterozygosity in human ovarian cancer on chromosome 19q. Gynecol. Oncol. 66:35-40.
8. Bookstein, R., J. Y. Shew, P. L. Chen, P. Scully, and W. H. Lee. 1990. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715.
9. Brindle, N. P., M. R. Holt, J. E. Davies, L. J. Price, and D. R. Critchley. 1996. The focal-adhesion vasodilator-stimulated phosphoprotein (VASP) binds to the proline-rich domain in vinculin. Biochem. J. 318:753-757.
10. Butt, E., K. Abel, M. Krieger, D. Palm, V. Hoppe, J. Hoppe, and U. Walter. 1994. cAMP- and cCMP-dependent protein kinase phophorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J. Biol. Chem. 269:14509-14517.
11. c-src mutated in the carboxy-terminal regulatory domain. Cell 49:83-91.
12. Chakraborty, T., F. Ebel, E. Domann, K. Niebuhr, B. Gerstel, S. Pistor, C. J. Temm-Grove, B. M. Jockusch, M. Reinhard, U. Walter, and J. Wehland. 1995. A novel focal adhesion factor directly linking the intracellularly motile Listeria monocytogenes and Listeria ivanovii to the actin-based cytoskeleton of mammalian cells. EMBO J. 14:1314-1321.
13. Cifone, M. A., and I. J. Fidler. 1980. Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc. Natl. Acad. Sci. USA 77:1039-1043.
14. Crawford, A. W., and M. C. Beckerle. 1991. Purification and characterization of zyxin, and 82,000-dalton component of adherens junctions. J. Biol. Chem. 266:5847-5853.
15. Cui, W., D. J. Fowlis, S. Bryson, E. Duffie, H. Ireland, A. Balmain, and R. J. Akhurst. 1996. TGF-β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86:531-542.
16. Dosaka-Akita, H., F. Hommura, H. Fujita, I. Kinoshita, M. Nishi, T. Morikawa, H. Katoh, Y. Kawakami, and N. Kuzumaki. 1998. Frequent loss of gelsolin expression in no-small cell lung cancers of heavy smokers. Cancer Res. 15:322-327.
17. Fearon, E., K. Cho, J. Nigro, S. Kern, J. Simon, J. Ruppert, S. Hamilton, A. Preisinger, G. Thomas, K. Kinsler, and B. Vogelstein. 1990. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247: 49-56.
18. Feinberg, A. P., and B. Vogelstein. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:6-13.
19. Fernadez, J. L. R., B. Geiger, D. Salomon, M. Z. Sabanay, and A. Ben-Ze'ev. 1992. Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA. J. Cell Biol. 119:427-438.
20. Fidler, I. J., and I. R. Hart. 1982. Biological diversity in metastatic neoplasms: origins and implications. Science 217:998-1003.
21. Freedman, V. H., and S. Shin. 1974. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3:355-359.
22. Gluck, U., D. J. Kwiatkowski, and A. Ben-Ze'ev. 1993. Suppression of tumorigenicity in simian virus 40-transformed 3T3 cells transfected with α-actinin cDNA. Proc. Natl. Acad. Sci. USA 90:383-387.
23. Gualberto, A., K. Aldape, K. Kozakiewicz, and T. D. Tlsty. 1998. An oncogenic form of p53 confers a dominant, gain of function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA 95:5166-5171.
24. Haber, D., and E. Harlow. 1997. Tumour-suppressor genes: evolving definitions in the genomic age. Nat. Genet. 16:320-322.
25. Haffner, C., T. Jarchau, M. Reinhard, J. Hoppe, S. M. Lohmann, and U. Walter. 1995. Molecular cloning, structural analysis and functional expression of the proline-rich focal adhesion and microfilament-associated protein VASP. EMBO J. 14:19-27.
26. Halbrugge, M., and U. Walter. 1989. Purification of a vasodilator-regulated phosphoprotein from human platelets. Eur. J. Biochem. 185:41-50.
27. Halbrugge, M., C. Friedrich, M. Eigenthaler, P. Schanzenbacher, and U. Walter. 1990. Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP- and cAMP-elevating vasodilators. J. Biol. Chem. 265:3088-3093.
28. Hartwell, L. H., T. A. Weiner, L. Kadyk, and B. Garvik. 1994. Cell cycle checkpoints, genomic integrity, and cancer. Cold Spring Harbor Symp. Quant. Biol. 49:259-263.
29. Holt, M. R., D. R. Critchley, and N. P. Brindle. 1998. The focal adhesion phosphoprotein, VASP. Int. J. Biochem. Cell Biol. 30:307-311.
30. Huang, H. J., J. K. Yee, J. Y. Shew, P. L. Chen, R. Bookstein, T. Friedmann, E. Y. Lee, and W. H. Lee. 1988. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563-1566.
31. Huttelmaier, S., O. Mayboroda, B. Harbeck, T. Jarchau, B. M. Jockusch, and M. Rudiger. 1998. The interaction of the cell-contact proteins VASP and vinculin is regulated by phosphatidylinositol-4,5-bisphosphate. Curr. Biol. 8:479-488.
32. Keely, P., L. Parise, and R. Juliano. 1998. Integrins and GTPases in tumour cell growth, motility and invasion. Trends Cell Biol. 8:101-106.
33. Kimura, Y., H. Koga, N. Araki, N. Mugita, N. Fujita, H. Takeshima, T. Nishi, T. Yamashima, T. Saido, T. Yamasaki, K. Moritake, H. Saya, and M. Nakao. 1998. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat. Med. 4:915-922.
34. Kinzler, K. W., and B. Vogelstein. 1997. Cancer-susceptibility genes: gatekeepers and caretakers. Nature 386:761-763.
35. Klein, G. 1987. The approaching era of the tumor suppressor genes. Science 238:1539-1545.
36. Knudson, A. J. 1993. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. USA 90:10914-10921.
37. Levine, A. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
38. Levine, A. J., J. Momand, and C. A. Finlay. 1991. The p53 tumor suppressor gene. Nature 351:453-456.
39. Li, L., J. E. Price, D. Fan, R. D. Zhang, C. D. Bucana, and I. J. Fidler. 1989. Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. J. Natl. Cancer Inst. 81:1406-1412.
40. Li, L., and S. N. Cohen. 1996. tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85:319-329.
41. Lo, S. H., E. Weisberg, and L. B. Chen. 1994. Tensin: a potential link between the cytoskeleton and signal transduction. Bioessays 16:817-823.
42. Lupton, S. D., L. L. Brunton, V. A. Kalberg, and R. W. Overell. 1991. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol. Cell. Biol. 11:3374-3378.
43. Machesky, L. M., and T. D. Pollard. 1993. Profilin as a potential mediator of membrane-cytoskeleton communication. Trends Cell Biol. 3:381-385.
44. 2-terminal domain inhibits the cell extension activity of the COOH-terminal domain. J. Cell Biol. 128:1081-1093.
45. KIP1 is haplo-insufficient for tumour suppression. Nature 396:177-180.
46. Narayanan, R., K. G. Lawlor, R. Q. Schaapveld, K. R. Cho, B. Vogelstein, P. Bui-Vinh Tran, M. P. Osborne, and N. T. Telang. 1992. Antisense RNA to the putative tumor-suppressor gene DCC transforms Rat-1 fibroblasts. Oncogene 7:553-561.
47. Pejovic, T. 1995. Genetic changes in ovarian cancer. Ann. Med. 27:73-78.
48. Prasad, G. L., R. A. Fuldner, and H. L. Cooper. 1993. Expression of transduced tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene. Proc. Natl. Acad. Sci. USA 90:7039-7043.
49. Raz, A., and B. Geiger. 1982. Altered organization of cell-substrate contacts and membrane-associated cytoskeleton in tumor cell variants exhibiting different metastatic capabilities. Cancer Res. 42:5183-5190.
50. Reinhard, M., M. Halbrugge, U. Scheer, C. Wiegand, B. M. Jockusch, and U. Walter. 1992. The 46/50 kDa phosphoprotein VASP purified from human platelets is a novel protein associated with actin filaments and focal contacts. EMBO J. 11:2963-2070.
51. Reinhard, M., K. Giehl, K. Abel, C. Haffner, T. Jarchau, V. Hoppe, B. Jockusch, and U. Walter. 1995. The proline-rich focal adhesion and microfilament protein VASP is a ligand for profilins. EMBO J. 14:1583-1589.
52. Reinhard, M., K. Jouvenal, D. Tripier, and U. Walter. 1995. Identification, purification, and characterization of a zyxin-related protein that binds the focal adhesion and microfilament protein VASP (vasodilator-stimulated phophoprotein). Proc. Natl. Acad. Sci. USA 74:5463-5467.
53. Ritland, S. R., V. Ganju, and R. B. Jenkins. 1995. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 12:277-282.
54. Rosenberg, J. E., D. K. Lisle, J. A. Burwick, K. Ueki, A. vonDeimling, H. W. Mohrenweiser, and D. N. Louis. 1996. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 13:2483-2485.
55. Rubio, M. P., K. M. Correa, K. Ueki, H. W. Mohrenweiser, J. F. Gusella, A. vonDeimling, and D. N. Louis. 1994. The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC. Cancer Res. 54:4760-4763.
56. Sadler, I., A. W. Crawford, J. W. Michelsen, and M. C. Beckerle. 1992. Zyxin and cCRP: two interactive LIM domain proteins associated with the cytoskeleton. J. Cell Biol. 119:1573-1587.
57. Schwartz, M. A. 1997. Integrins, oncogenes, and anchorage independence. J. Cell Biol. 39:575-578.
58. Scoles, D. R., D. P. Huynh, P. A. Morcos, E. R. Coulsell, N. G. G. Robinson, F. Tamanoi, and S. T. Pilst. 1998. Neurofibromatosis 2 tumor suppressor schwannomin interacts with βII-spectrin. Nat. Genet. 18:354-359.
59. Shaw, R. J., A. I. McClatchey, and T. Jacks. 1998. Regulation of the neurofibromatosis type 2 tumor suppressor protein, Merlin, by adhesion and growth arrest stimuli. J. Biol. Chem. 273:7757-7764.
60. Suetsugu, S., H. Miki, and T. Takenawa. 1998. The essential role of profilin in the assembly of actin for microspike formation. EMBO J. 17:6516-6526.
61. Takeuchi, K., N. Sato, H. Kasahara, N. Funayama, A. Nagafuchi, S. Yonemura, S. Tsukita, and S. Tsukita. 1994. Perturbation of cell adhesion and microvilli formation by antisense oligonucleotides to ERM family members. J. Cell Biol. 125:1371-1384.
62. Tang, B., E. P. Bottinger, S. B. Jakowlew, K. M. Bagnall, J. Mariano, M. R. Anver, J. J. Jetterio, and L. M. Wakefield. 1998. Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency. Nat. Med. 4:802-807.
63. Turner, C. E., J. R. Glenney, and K. Burridge. 1990. Paxillin: a new vinculin binding protein present in focal adhesions. J. Cell Biol. 111:1059-1068.
64. Venkatachalam, S., Y. Shi, S. N. Jones, H. Vogel, A. Bradley, D. Pinkeland, and L. A. Donehower. 1998. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17:4657-4667.
65. Waldmann, R., M. Nieberding, and U. Walter. 1987. Vasodilator-stimulated protein phophorylation in platelets is mediated by cAMP- and cGMP-dependent protein kinases. Eur. J. Biochem. 167:441-448.
66. Weiss, E. E., M. Kroemker, A. Rudiger, B. M. Jockusch, and M. Rudiger. 1998. Vinculin is part of the cadherin-catenin junctional complex: complex formation between α-catenin and vinculin. J. Cell Biol. 141:755-764.
67. White, R. L. 1998. Tumor suppressing pathways. Cell 92:591-592.
68. Wilkins, J. A., M. A. Risinger, and S. Lin. 1986. Studies of proteins that co-purify with smooth muscle vinculin: identification of immunologically related species in focal adhesions of nonmuscle and Z-lines of muscle cells. J. Cell Biol. 102:1483-1494.
69. Xie, W., L. Li, and S. N. Cohen. 1998. Cell cycle-dependent subcellular localization of the tsg101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc. Natl. Acad. Sci. USA 95:1595-1600.
70. Zimmer, M., T. Fink, L. Fiselore, W. Hauser, K. Scherer, P. Lichter, and U. Walter. 1996. Cloning of the VASP (vasodilator-stimulated phosphoprotein) genes in human and mouse: structure, sequence, and chromosomal localization. Genomics 36:227-233.